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Abstract 19
Bacterial vaginosis (BV) is a prevalent multifactorial disease of women in their reproductive 20 years characterized by a shift from the Lactobacillus spp. dominated microbial community 21 towards a taxonomically diverse anaerobic community. For unknown reasons, some women 22 do not respond to therapy. In our recent clinical study, out of 37 women diagnosed with BV, 23 31 were successfully treated with metronidazole, while 6 still had BV after treatment. To 24 discover possible reasons for the lack of response in those patients, we performed a 25 metatranscriptome analysis of their vaginal microbiota, comparing them to patients who 26 responded. Seven out of 8 Cas genes of Gardnerella vaginalis were highly up-regulated in 27 non-responding patients. Cas genes, in addition to protecting against phages, might be 28 involved in DNA repair thus mitigating the bactericidal effect of DNA damaging agents like 29 metronidazole. In the second part of our study, we analyzed the vaginal metatranscriptomes of 30 four patients over three months and showed high in vivo expression of genes for pore-forming 31 toxins in L. iners and of genes encoding enzymes for the production of hydrogen peroxide and 32 D-lactate in L. crispatus. 33 34 Introduction 46 The healthy vaginal microbiome is characterized by low pH and low diversity and can be categorized into community state types (CSTs) that are dominated by different Lactobacillus 48 spp. such as L. crispatus, L. iners, L. gasseri and less frequently L. jensenii or a more diverse 49 community (1) . Bacterial vaginosis (BV) is a frequent multifactorial disease of women in 50 their reproductive years that is characterized by a shift of this Lactobacillus spp. dominated 51 bacterial community to a community of various mostly anaerobic bacteria (2). BV is 52 associated with a higher risk of preterm birth and of acquiring sexually transmitted infections 53 such as HIV (3). The most common bacteria found in BV, identified by 16S rRNA gene 54 sequencing, are Gardnerella, Atopobium, Prevotella, Bacteroides, Peptostreptococcus, 55
Mobiluncus, Sneathia, Leptotrichia, Mycoplasma and BV associated bacterium 1 (BVAB1) to 56 BVAB3 of the order Clostridiales. Recently, three CSTs dominated by Gardnerella vaginalis, 57
Lachnospiraceae and Sneathia sanguinegens, respectively, have been described (4). In our 58 recent clinical study S. amnii was identified as the best biomarker for BV (5). 59
The most important pathogen in BV is Gardnerella vaginalis (6). It is currently the only 60 described species in the genus Gardnerella, but genome comparisons suggest that it can be 61 separated into four genetically isolated subspecies (7) . While they cannot be resolved by 16S 62 rRNA gene sequencing, the universal target from the chaperonin-60 gene separates the 63 species into the same four subgroups (group A, clade 4; subgroup B, clade 2; subgroup C, 64 clade 1; subgroup D, clade 3) (6, 8, 9) . All four subgroups of G. vaginalis can be detected in 65 the vaginal microbiota of healthy women throughout the menstrual cycle (10). Subgroup A 66 and C define distinct CSTs in health (11). Isolates from the four subgroups of G. vaginalis 67 differ in their virulence as well as in their resistance against metronidazole. The sialidase 68 activity of G. vaginalis is an important virulence factor and it was detected in all isolates from 69 subgroup B and few isolates of subgroup C but not in subgroups A and D isolates (12). The 70 presence of sialidase activity is used for diagnosis of BV in a commercial kit (13). Resistance 71 against metronidazole was found in subgroups A and D isolates, while those from subgroups 72 B and C were highly susceptible (14) . 73
Metronidazole is a widely applied chemotherapeutic agent used to treat infectious diseases 74 caused by anaerobic bacteria, and it is the first-line antibiotic for treating BV (15, 16) . 75
Metronidazole is a prodrug which requires enzymatic reduction within the cell, which occurs 76 under anaerobic conditions only, to transform it into an active form (17). Activated 77 metronidazole acts by covalently binding to DNA, disrupting its helical structure and causing 78 single and double strand breaks that lead to DNA degradation and death of the pathogens 79 (17). Resistance can therefore be mediated by lack of activation of the prodrug, or by repair of 80 DNA damage, and has been studied in various pathogens. In Helicobacter pylori and 81
Campylobacter spp. ferredoxin, ferredoxin/ferredoxin-NADP reductase (FNR) and 82 nitroreductase contribute to metronidazole resistance (17). In Bacteroides fragilis, genes 83 responsible for DNA repair like recA and recA-mediated autopeptidase (Rma) and a gene 84 named nitroimidazole resistance gene (nim) encoding a nitroimidazole reductase were shown 85 to confer resistance against metronidazole (18, 19) . Failure of BV treatment by metronidazole 86 is relatively rare (5, 20) .It is unclear if it is caused by resistance of the BV pathogens to 87 metronidazole, and which mechanisms are acting in vivo. A recent study has demonstrated 88 that failure of treatment of BV with metronidazole is not associated with higher loads of G. 89 vaginalis and A. vaginae (21). Isolates from G. vaginalis subgroups A and D are intrinsically 90 resistant against metronidazole, but the underlying mechanism is unknown (14). 91
Until now, the majority of studies regarding the vaginal microbiota have focused on 16S 92 rRNA gene sequencing, answering only questions on the taxonomic composition of bacterial 93 communities but not on their functions (2). A metatranscriptome analysis comparing vaginal 94 swabs from two women with BV with two healthy subjects showed that L. iners upregulates 95 transcription of the cholesterol-dependent cytolysin (CDC) and of genes belonging to the 96 clustered regularly interspaced short palindromic repeats (CRISPR) system in BV (22) . No 97 study has investigated the activity shifts of the vaginal microbiota during antibiotic treatment 98 of BV. 99
We had previously analyzed the vaginal microbiota in the context of a clinical trial using 16S 100 rRNA gene sequencing (5). Of 37 patients diagnosed with BV and included in this study, 31 101 were initially cured by a single oral dose of metronidazole. Six patients did not respond, i.e. 102 they were still diagnosed with BV according to Nugent score after antibiotic therapy. Here we 103 asked if differences in the activity of the microbiota might be responsible for the lack of 104 response in those six patients. We therefore analyzed their metatranscriptomes at the time of 105 diagnosis of BV (visit 1) and after treatment with metronidazole (visit 2) and compared them 106 to those of 8 patients that responded to treatment according to Nugent score. 107
The high rate of recurrence is another crucial problem for BV treatment. The one-year 108 recurrence rate of BV ranges from 40% to 80% after therapy with metronidazole (23) or 109 clindamycin cream (24). CST dominated by L. iners might have an increased probability to 110 shift to a dysbiotic state (22, 25, 26) . In the second part of our study, we therefore followed the 111 activity of the microbiota from four of the patients that initially responded to metronidazole 112 treatment over a period of 3 months (visit 3-5) and analyzed gene expression of L. crispatus 113 and L. iners in vivo. 114
We show the importance of G. vaginalis for BV, which can be massively underestimated 115 using 16S rRNA gene sequencing. The relative abundance of the four subgroups of G. 116 vaginalis could be determined in responders and non-responders. Transcripts potentially 117 leading to lack of response to metronidazole treatment were identified. CRISPR-Cas genes are 118 suggested as a novel mechanism of G. vaginalis to mitigate the DNA damaging effect of 119 metronidazole. L. iners highly expressed genes for pore-forming toxins in vivo, and in L. 120 crispatus the most highly expressed transcripts in vivo encoded enzymes for D-lactate and 121 hydrogen peroxide production. 122 123
Results

124
Study population and overview of sequencing results 125
Construction of the reference genome and gene databases for taxonomic and activity 140
profiling 141
Human reads comprised ~11% (BV) versus ~56% (non-BV) of the total putative mRNA reads 142 based on the standard Kraken (27) database (Table S1 sheet 2). This suggests that the 143 bacterial load is much lower in non-BV than in BV since the human contamination is much 144 higher in non-BV. Using the standard Kraken database, only 41% of total putative microbial 145 (non-human) mRNA reads could be assigned taxonomically (Table S1 sheet 2). To improve 146 the fraction of taxonomically assignable reads we then constructed a refined database 147 (ref_Genome) which combined the urogenital subset of the HMP (28) database (147 148 genomes) and all species which are not included in the urogenital subset of the HMP database 149 but detected by the standard Kraken database with an abundance >1% (7 genomes). We also 150 added S. amnii and S. sanguinegens which had previously been shown to be highly abundant 151 based on 16S rRNA gene sequencing (5) but were not contained in either HMP or the 152 standard Kraken reference database. There are four G. vaginalis strains in the HMP database, 153 of which one belongs to subgroup A and three belong to subgroup C. Given the importance 154 and high intra-species diversity of G. vaginalis, we added 5 additional G. vaginalis genomes 155 based on the genome tree reported in the NCBI database and the completeness of the genome 156 assembly; these five strains cover all four subgroups. We added the genomes of Gardnerella 157 sp. 26-12 and Gardnerella sp. 30-4 which were isolated from the bladder recently (29). They 158 were classified into G. vaginalis subgroup A based on sequence homology (29). In total, this 159 database contained 163 bacterial genomes from 105 species (Table S1 sheet 3). Using this 160 database, the rate of taxonomically classified putative microbial mRNA reads could be 161 improved to 86% on average (Table S1 sheet 2). 162
For functional assignment, we constructed a reference gene database (ref_Gene) ( Table S1  163 sheet 4). It was based on the same genomes as the ref_Genome database, except that the seven 164 additional Gardnerella spp. genomes were not included because of the low quality of the 165 annotation of coding sequences. The ref_Gene database contained 301,323 genes. To 166 investigate the activity shifts of the communities, we mapped the cleaned metatranscriptomic 167 reads to the ref_Gene database using BWA. In total, 78% of total putative microbial mRNA 168 reads could be mapped to the ref_Gene. Per sample, on average 8.9 million microbial mRNA 169 reads could be mapped with MAPQ >10 (Table S1 sheet 2). On average less than 14 species contributed >90% of the mapped reads in BV and 3 species 179 accounted for >90% of the mapped reads in non-BV (Fig. 1C ). The individual dominance 180 plots showed the same pattern where 10 species contributed >90% of the metatranscriptomes 181 for most patients in BV. In non-BV, this number was 2 for most patients and the dominance 182 curves were extremely steep. For comparison, in the periodontal metatranscriptome more than 183 100 species were required to cover 90% of mapped reads (30). These data show that the active 184 microbiota in BV is much less diverse than suggested by 16S rRNA gene sequencing. 185 G. vaginalis was the most dominant active species in BV. To estimate the relative abundance 186 of the four subgroups of G. vaginalis, we extracted all reads assigned to G. vaginalis from the 187 metatranscriptomes and assigned them to the four strains representing subgroups A-D, 188 respectively (409-05, 00703Bmah, HMP9231, 00703Bmash) using Kraken. For this analysis, 189 we used samples from visit 1 where G. vaginalis reads comprised at least 20% of all reads, 190 which included all 6 patients without response to treatment, and 5 of the 8 patients that 191 responded to treatment. Figure 1D shows that on average >95% of the reads could be mapped 192 to the four subgroups and only on average 7% were assigned ambiguously. In those patients 193 that did not respond to treatment, subgroups A and D comprised 68.5±17.2 % of all reads, 194 while they accounted for 30.5±29.3% of all reads in patients that responded to treatment 195 (Wilcoxon test P=0.0520). We observed that Gardnerella spp. previously isolated from the 196 bladder (Gardnerella sp. 26-12 and Gardnerella sp. 30-4) (29) contributed on average 6% of 197 all taxonomically assigned reads in BV ( Fig. S1 ). 198
Comparison of the taxonomic composition of vaginal fluid samples between 199 metatranscriptome and 16S rRNA gene sequencing 200
We compared the taxonomic composition determined using 16S rRNA sequencing previously 201 (5) and the taxonomic composition of the metatranscriptome determined here by Kraken with 202 the ref_Genome database. In non-BV, we did not observe any considerable difference for the 203 four most abundant species (Table S1 sheet 6), while in BV large differences between the two 204 datasets were found. Fig. 2 shows the top 12 most abundant taxa identified using 16S rRNA 205 gene sequencing and metatranscriptomics, respectively. Most of the abundant species 206 identified in the mRNA sequencing data set were also identified using 16S rRNA gene 207 amplicon sequencing, although usually at different abundances. For example, A. vaginae 208 comprised 13% of all reads based on 16S rRNA gene sequencing, but only 11% in the 209 metatranscriptome dataset. The most pronounced difference was observed for G. vaginalis 210 which comprised on average 47% of relative abundance in the metatranscriptome and on 211 average only 5% in the 16S rRNA sequencing data. Several additional differences were 212 found: Higher level taxa like Veillonellaceae (family) or Parvimonas (genus) are not listed 213 among the top 12 taxa of the metatranscriptome, because mapping occurred to species level, 214 and the abundance of individual species of these higher order taxa was too low to be found 215 among the top 12 taxa (Table S1 sheet 6). BVAB2 is readily detected by PCR and is an 216 important indicator of BV, but it is not yet cultivated and so there is no genome available to 217 map the reads against. 218
Global community profiling in non-BV and BV 219
In order to profile the function of the communities, all cleaned putative mRNA reads (Table  220 S1 sheet 2) were mapped using BWA onto the ref_Gene database annotated with KEGG 221 ortholog (KO) genes. We used principal component analysis (PCA) to visualize the difference 222 between the microbiota in BV and non-BV on the level of taxonomy (16S rRNA gene) ( This reversal is even stronger on the level of KO genes ( Fig. 3C ): Samples from BV form a 233 tight cluster, while those from non-BV vary widely. It is the opposite pattern than that found 234 for the phylogenetic marker gene. The KO genes that contributed most to these differences in 235 non-BV were phosphofructokinase isozyme pfkA (31) and ribosomal protein coding genes 236 rpsI, rpmF and rplU (32,33). In BV, msmE, cycB and pflD genes that encode proteins 237 involved in carbohydrate uptake and metabolism (34,35) were stably higher expressed. 238
In vivo expression of putative metronidazole resistance associated genes in G. vaginalis 239
To clarify the possible contribution of genes related to metronidazole resistance in Gram 240 positive pathogens to the difference in response to treatment of the vaginal microbiota, we 241 examined their expression (Table S1 sheet 9) in G. vaginalis. For this analysis, BV 242 communities from 11 patients at visit 1 were analyzed in which the level of G. vaginalis 243 transcripts was >20%. Six of these patients did not respond to treatment and five responded. 244
Although A. vaginae and S. amnii are also key players in BV we could not analyze them here 245 since there were too few samples dominated by them. As shown in Fig. 4A , there was no clear 246 expression pattern for most of these genes (detailed data in Table S1 sheet 9). The only 247 significantly changed gene expression was that of the gene encoding ferredoxin which was 248 less active in G. vaginalis in non-responding patients (fold change=1.67, Wilcoxon test 249 P=0.00866 based on relative abundance = read count of given genes of G. vaginalis / read 250 count of G. vaginalis %). 251
CRISPR associated protein coding genes of G. vaginalis were strongly up-regulated in 252 vaginal fluids of patients not responding to treatment 253
We then performed a global analysis of differential expression of KO genes of G. vaginalis in 254 these same communities (visit 1, 11 BV samples with >20% transcripts from G. vaginalis 255 including 6 patients that did not respond to treatment and 5 that responded). We observed that 256 there were 9 KO genes highly up-regulated with FDR <= 0.05 (log2 fold change up to 9.46) 257 in communities without response. Strikingly, among the most strongly up-regulated KO 258 genes, seven were cas genes (36) (Fig. 4B ). In total there were 8 different G. vaginalis 259 CRISPR-associated (Cas) genes found in the genomes, namely cas1-3, casA-E, of which 260 seven were up-regulated (cas1-3, casA-D). 261
There were 9 KO genes down-regulated but the fold change values were not as high as for the 262 up-regulated genes. fucP (fucose permease) was identified as the most strongly down-263 regulated gene with a log2 fold change of -4.24. 264
Time course of activity profiles and recurrence 265
In the second part of our study, we analyzed the metatranscriptome of vaginal fluid samples 266 from four of the patients that initially responded to therapy with metronidazole for the 267 complete duration of the clinical trial. Two of these patients experience recurrence of BV, and 268 two remained stably non-BV. Five timepoints were analyzed of which the first two were 269 already shown in Fig. 1A . They represented acute BV (visit 1) and after metronidazole 270 therapy (visit 2). Here, we also show visit 3-5, which were all non-BV, with the exception of 271 recurrence at visit 5 in patient 04_001 and at visit 3 in patient 06_004. Fig. 5A shows the 272 taxonomic composition of the communities. In one of the two patients that stably maintained 273 a non-BV status L. crispatus, and in the other L. iners dominated the microbiota. The 274 principal components analysis of the activity profiles is shown in Fig. 5B . In acute BV, 275 samples from all four patients clustered together (red circle). After the treatment, samples 276 from patient 08_006 who was stably non-BV moved into a very dense and distinct cluster 277 (illustrated by the arrow 1 and enclosed by a green circle). Samples from patient 13_019 who 278 also remained stably non-BV moved to a different cluster after treatment, shown by arrow 2 279 and encircled blue. 280
The activity shifts in patient 06_004, who experienced recurrence at visit 3, were especially 281 noteworthy: After treatment, the community moved towards an activity profile distinct from 282 all others (arrow 3). The recurrence of BV caused the community to shift back to the BV 283 cluster (red circle, arrow 4). At visit 4, the community moved to the non-BV cluster (blue 284 circle) and the patient became non-BV according to the Nugent score. We speculate that there 285 was an unknown intervention after visit 3 which changed the microbiome but this was not 286 recorded. Interestingly, the other case of recurrence (patient 04_001) had a different 287 progression. From visit 2 to 4, patient 04_001 was non-BV and these samples clustered 288 together in the "non-BV" cluster indicated by the blue circle. At visit 5, however, patient 289 04_001 had recurrent BV and the community shifted back again to the BV cluster. 290
Transcriptomics of L. iners and L. crispatus in vivo 291
The KO genes in terms of FDR value, 64 were up-regulated in L. crispatus, Remarkably, genes 304 encoding enzymes involved in the production of H 2 O 2 (pyruvate oxidase, NADH oxidase, 305 glycolate oxidase) (37,38) were highly expressed in L. crispatus (Table S1 sheet 8, KO genes 306 colored in blue). D-lactate dehydrogenase (K03778) was the most highly expressed gene in L. 307 crispatus (log2 CPM = 13.3, Table S1 sheet 8, colored in light green) and this gene is absent 308 in the genome of L. iners. On the other hand, we found that inerolysin (INY) was highly 309 expressed (log2 CPM =9.8) in L. iners, but absent in the genome of L. crispatus (Table S1  310 sheet 8, colored in red). Interestingly, we also found the orthologous gene (K11031) of 311 inerolysin known as vaginolysin (39) highly expressed in G. vaginalis (details in Table S1 312 sheet 7). Hemolysin C, another pore forming toxin, was highly expressed (log2 CPM = 9.8) in 313 L. iners but absent in L. crispatus. 314
Discussion
315
The aim of this study was to identify activity patterns in the vaginal fluid microbiota in BV 316 and after metronidazole therapy. In particular, we compared the transcriptional profiles of G. 317 vaginalis in vaginal microbiota from patients who did and did not respond to metronidazole 318 treatment, respectively. This is the first study to investigate the activity alterations of the 319 vaginal microbiota from patients with BV during treatment with the antibiotic metronidazole 320 using the metatranscriptomics approach. We found several changes in gene expression in non-321 responding patients that might contribute to resistance against metronidazole by either not 322 activating the pro-drug or repairing DNA damage. 323
G. vaginalis was the most dominant active species in BV. G. vaginalis can be divided into 324
four phylogenetic subgroups which may in the future be described as subspecies and which 325 differ in virulence and susceptibility to metronidazole (6,12). We found transcripts from all 326 four subgroups in all patients, as previously shown based on sequencing of the universal 327 target cp-60 gene (6,9,11). Interestingly, in those patients that did not respond to treatment, 328
Gardnerella subgroups A and D which are resistant to metronidazole (14) were slightly more 329 abundant. 330
Sequencing of phylogenetic marker genes like the 16S rRNA gene or the cpn60 universal 331 target is a fast and sensitive method to profile the microbiota composition, but it does not 332 provide functional information and is prone to PCR bias. Moreover, DNA from dead cells 333 might also be detected. Therefore, we compared the taxonomic composition of the transcripts 334 with that of the 16S rRNA genes determined previously in those samples (5). We observed 335 that G. vaginalis comprised on average 47% of all transcripts in BV, while only 5% of 16S 336 rRNA genes were assigned to this species. This suggests that G. vaginalis is transcriptionally 337 more active than other vaginal bacteria; moreover, the commonly used 27F primer was 338 previously shown to underrepresent G. vaginalis (40). Other differences between the two 339 methods are caused by the low taxonomic resolution of the 16S rRNA gene, especially of 340 short amplicons, where a large fraction of 16S rRNA reads is assigned to higher level taxa, 341 e.g. genus or family. By contrast, the metatranscriptome reads are mapped to genomes and so 342 have species level resolution. Finally, transcripts can only be mapped if a genome is available. 343
If the species in question has not yet been cultivated, as for example the BVAB strains, then 344 reads cannot be assigned. In the periodontal pocket microbiota, about 50% of all reads cannot 345 be mapped to any bacterial genome (30). By contrast, the vaginal microbiota is much less 346 diverse and most of its representatives have been cultivated; using the improved ref_Genome 347 database, we were able to map 86% of all reads, indicating that uncultivated taxa did not 348 contribute very significantly to the active community in BV and after metronidazole therapy. 349
Low diversity in health and high diversity in BV is a hallmark of BV and it is so striking that In our metatranscriptome analysis we found evidence for mechanisms that hinder the 359 activation of the metronidazole prodrug, or mitigate the damage that metronidazole inflicts on 360 DNA, and thus could be important reasons for the lack of response in some women. 361
We show that the ferredoxin gene of G. vaginalis was less active in those patients that did not 362 respond to metronidazole. As an electron carrier, ferredoxin is downregulated in H. pylori There were many factors observed by laboratory or genomic studies (37,51,52) which suggest 406 that more protection against dysbiosis is provided by L. crispatus rather than by L. iners. Here 407 we analyzed which genes are actually highly expressed in vivo: We observed that genes 408 encoding proteins for the production of H 2 O 2 and D-lactic acid were highly expressed in L. 409 crispatus. H 2 O 2 inhibits BV associated bacteria, but it has been questioned if its level in the 410 vaginal milieu is high enough, and it was suggested that lactic acid is more protective (53). In 411 L. iners, the genes for the pore-forming toxins inerolysin and hemolysin C were highly active, Involving Human Subjects. Principles and guidelines for good clinical practice were followed. 432
The study was registered on ClinicalTrials.gov with the identifier NCT02687789. Briefly, 433 women were included into the clinical trial if they were BV positive according to Amsel 434 criteria and Nugent score and were biofilm positive on vaginal epithelial cells and positive for 435 extracellular polysaccharides (EPS) in urine. For treatment of acute BV, they received 2 g of 436 metronidazole orally and were afterwards treated with an intravaginal pessary for three weeks, 437 twice a week. Samples were taken during acute BV (visit 1), after receiving metronidazole 7 438 to 28 days after visit 1 (visit 2), after pessary application one week after visit 2 (visit 3), after 439 continued pessary application two weeks after visit 3 (visit 4) and during follow up three 440 months after visit 4 (visit 5). 441
The aim of the clinical trial had been to compare the effectiveness of two different types of 442 pessary. The results and the taxonomic composition of the vaginal microbial communities 443 have been reported (5). For the metatranscriptome analysis reported here, we chose a subset 444 of 14 patients from the clinical trial. These 14 patients consisted of two groups named "with 445 response to treatment" (n = 8) and "no response to treatment" (n = 6) ( Fig. 1 ). Among the 446 eight patients who responded to treatment, six had no recurrence and two experienced 447 recurrence during the three months follow-up. For the analysis of lack of response to 448 metronidazole, samples from all 14 patients were analyzed at two timepoints, acute BV (visit 449 1) and 7 to 28 days after antibiotic treatment (visit 2) (28 samples in total). For the analysis of 450 recurrence, samples from all 5 visits were analyzed for 4 patients (two without recurrence and 451 two with) (20 samples in total). These four patients all received the commercially available 452 lactic acid pessary after metronidazole therapy at visit 3 and 4. Nugent score >6 was used to 453 determine BV status since it is considered the gold standard for BV diagnosis (55) ( Table S1  454 sheet 1). The BV status at visit 5 was determined by Amsel criteria as there was no Nugent 455 score available at that timepoint. The sample ID was obtained by concatenating the patient ID 456 and letters "a" to "e" indicating visit 1 to 5. 457 The ref_Genome database contained 163 bacterial genomes from 105 species of bacteria, 493 including 147 genomes from the urogenital subset of the HMP reference genome sequence 494 data (HMRGD). The complete list of reference genomes in the ref_Genome database can be 495 found in Table S1 sheet 3. All results on the taxonomic composition in this study were 496 achieved based on this database. 497
Sample collection and transport 458
Short reads alignment by BWA 498
Kraken was used for taxonomy classification, while BWA was applied to determine the 499 expression of genes. A reference gene database named ref_Gene was constructed which 500 contained the genes from the urogenital tract subset of the HMRGD and the genes from 9 501 additional genomes (Table S1 sheet 4). The genes of Gardnerella sp. 26-12, Gardnerella sp. 502 30-4 could not be included because only less than half of their CDS are available (around 503 1000 genes). The short reads alignment was performed using BWA with the BWA-MEM (58) 504 algorithm. A mapping seed length of 31 which is much longer than the default seed length 19 505 was applied to achieve reliable alignments. Reads that mapped with mapping quality score 506 (MAPQ) lower than 10 were excluded. MAPQ contains the Phred-scaled posterior probability 507 that the mapping position is wrong (59). 508
KEGG Orthologous (KO) gene annotation of ref_Gene database 509
The ref_Gene database was annotated using KEGG prokaryote protein sequences. The KEGG 510 prokaryote protein sequence database represents a non-redundant protein dataset of Bacteria 511 and Archaea on the species level and contains about 7 million non-redundant peptide 512 sequences grouped into 14,390 distinct KO genes. A KO gene contains several genes from 513 different species with similar function. DIAMOND (60), a much faster alternative to 514 BLASTX was applied to map the ref_Gene sequences against the KEGG prokaryote protein 515 sequence database with its "more sensitive mode". To obtain reliable annotation, only 516 alignments with sequence identity >=50 and E-value <= 1e-5 and query coverage >= 70% 517 were taken into account. By annotating the genes in the ref_Gene database to KO genes, we 518 were able to determine the expression profile of KO genes, and investigate the activity shifts 519 in BV based on differential expression analysis of KO genes. The cumulative dominance 520 analysis and PCA were carried out using Primer 7 (61). 521
Differential expression (DE) analysis 522
All differential expression (DE) analyses were performed using the R package edgeR (62). 523
The Benjamini Hochberg (BH) method was used to correct the p value of DE analysis with 524 the false discovery rate (FDR) for multiple comparisons. Genes with FDR smaller than 0.05 525 were considered as significantly differentially regulated. The sample groups defined for each 526 comparison are listed in Table S1 sheet 1. 527
Detection of putative metronidazole resistance related genes 528
To detect the expression of previously reported putative metronidazole resistance genes such 529 as recA, recA-mediated autopeptidase (Rma), peroxiredoxin, nitroimidazole resistance protein 530 (NIM), ferredoxin/ferredoxin-NADP reductase (FNR), nitroreductase and ferredoxin, we 531 examined the expression level of these genes for G. vaginalis in the vaginal community from 532 patients without response to metronidazole treatment (n = 6) as well as with response (n = 4). 533
As most of these genes do not have corresponding KO genes, we annotated the ref_Gene 534 database based on the sequences of these genes using BLASTN. The sequences were 535 retrieved from ENA by key words of each "ferredoxin, NADPH flavin oxidoreductase, 536 nitroreductase, peroxiredoxin, pyruvate ferredoxin oxidoreductase, recA, nitroimidazole 537 resistance" plus G. vaginalis. In total, 155 unique sequences of G. vaginalis were obtained for 538 the annotation of ref_Gene database. The identification of duplicate sequences was done by 539 SeqKit (63). 540
Availability of data and material 541
The sequencing data have been deposited in the European Nucleotide Archive with accession 542 number PRJEB21446. 543 putative bacterial mRNA reads were mapped to the ref_Genome database using Kraken (see 783 Methods for details). BV status was determined by Nugent score. In C, the "BV" and "NBV" 784 in the parenthesis indicate BV and non-BV, respectively. 785 
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